Roadshow
IntelliPrep TRIO 240 Sample Preparation System
PlexBio’s proprietary core technology " Precision Image Code (πCode) MicroDiscs " utilizes Taiwan’s semiconductor technology with photolithography processes to imprint a unique pattern on each πCode and achieves simultaneously detecting hundreds of targets from one sample test. With the use of TRIO 240 three-in-one Automated Nucleic Acid Extractor and IP5000 Automation System, one touch to complete sample-to answer processes from automated nucleic acid extraction, quantification, PCR reaction plate preparation, πCode reaction and image recognition analysis, to meet the needs of top clinical laboratory instrumentation requirements, rapid tests, and high clinical testing capacity. The customized reagents kits using πCode multiplexing detection could be applied for various downstream applications such as genetic testing, pathogen diagnosis, cancer management and immunoassays in the market. The automated integrated system has advantages for high detection sensitivity, and high throughput multiplexing detection and detection cost-effectiveness to fully meet the needs of clinical applications.
IntelliPrep TRIO 240 Sample Preparation System
FEATURES
- Primary Sample Processing
not required for extra sample pre-treatment - Standardized Workflow
reduce human errors - Reliable Performance
good yield, good purity - Versatile Applications
open system to meet application demands - Ease to Use
intuitive user interface for operation - Sample Data Management
fully data traceability
- Established 2009
- Company PlexBio Co., Ltd.
- Telephone 886-2-2627-5878
- Address 6F-1, No. 351, Yangguang St., Neihu District, Taipei City
PlexBio Co., Ltd. founded in 2010, is dedicated to the development of innovative, high-performance, and diversified in vitro diagnostic reagents and instrument platforms. With PlexBio’s proprietary core technology, Precision Image Code (πCode) MicroDiscs, could achieve simultaneously detecting hundreds of targets from one sample test. Meanwhile, we focus on developing a complete automated Sample-to-Answer detection system, which includes a TRIO 240 three-in-one Automated Nucleic Acid Extractor and IP5000 Automation System for one-stop solution. With the patented technologies, the complete automation solutions offer a high throughput multiplexing detection capability to meet assay cost-effective. PlexBio are committed to the delivery of accurate, simple, and rapid tests for high-quality innovative products and services in the market, to elevating clinical and precision medicine development. And we expect to be a major player in the global IVD market.
2023
- Received IVDR approval for IntelliPlex™ 1000 πCode Processor
- Received IVDR approval for PlexBio™ 100 Fluorescent Analyzer
2022
- Automated Multiplexing Molecular In-vitro Diagnostic System won Taipei Biotech Award 2022 Innovative Awards-Silver medal
- PlexBio was invited by Bio-Aisa to exhibited the newest innovative automatic high-throughput multiplexing molecular diagnostic platform during the trade show.
2021
- Received trademark approval in Taiwan for “IntelliPrep”
- Launched IntelliPlex™ Lung Cancer Panel with IntelliPlex Platform in BioAsia Taiwan
- Patent filed in Singapore for “Image differentiated multiplex assays”
- Patent filed in Japan for “Image differentiated multiplex assays”
- Success sales to Shanghai Yikon Medical Laboratory Co., Ltd. for IntelliPlex Lung Cancer Panel
- Patent filed in Taiwan for “Image differentiated multiplex assays”
- Received trademark approval in Japan for “IntelliPlex” (word mark)
- Success regular sales to LIHPAO LIFE SCIENCE CORP for Automated Nucleic Acid ExtractionSystem and IntelliPlex™ SARS-CoV-2 Extraction Kit
- Collaboration with Chiang Mai University, Thailand forπCode assay development on IntelliPlex Platform
- Patented filed in AUS for “Image differentiated multiplex assays”
- Launched IntelliPlex™ SARS-CoV-2 Variant Analysis Kit both in Taiwan and Japan
- Received FSC for IntelliPlex™ SARS-CoV-2 Detection Test Kit
- Success co-development with Denka Seiken Co. Ltd. for IntelliPlex™ SARS-CoV-2 Variant Analysis Kit
- Received TFDA approval for IntelliPlex™ SARS-CoV-2 Detection Test Kit
- Membership of 5th Liquid Biopsy for Precision Oncology Summit
- Patent filed in US for “Image differentiated multiplex assays for multiplex detection of DNA mutations”
- Received FSC for IntelliPlex™ SARS-CoV-2/Flu Kit
- Success sales to SHUWEN BIOTECH CO., LTD. for IntelliPlex Lung Cancer Panel